Illumina
ILMN
$141.92
+0.17%
Illumina Inc. is a global leader in genomic sequencing and array-based technologies, providing critical tools and services for analyzing genetic material across life sciences and clinical diagnostics. The company holds a dominant market position as the primary provider of high-throughput sequencing systems, with over 90% of its revenue derived from sequencing instruments, consumables, and related services, effectively making it the platform standard for large-scale genetic analysis. The current investor narrative revolves around the company's recovery and strategic refocus following a period of significant challenges, including the costly and controversial acquisition of GRAIL, with attention now centered on core business execution, margin improvement, and capital allocation as it aims to re-establish consistent growth and profitability in the foundational genomics market.…
ILMN
Illumina
$141.92
Investment Opinion: Should I buy ILMN Today?
Rating & Thesis: Hold. Illumina is a high-quality company in the midst of a successful operational turnaround, but its premium valuation fully reflects this recovery, leaving limited near-term upside without evidence of accelerating revenue growth. The mixed analyst sentiment, with ratings spanning Overweight to Underweight, supports this cautious stance, as consensus lacks a clear catalyst for the next leg up.
Supporting Evidence: The Hold rating is supported by four key data points: 1) A rich forward P/E of 24.11x, which is elevated for the sector, 2) Modest YoY revenue growth of 4.98% in Q4 2025, which is insufficient to drive multiple expansion, 3) Exceptional profitability metrics (28.8% net margin, 31.22% ROE) that are already priced in, and 4) Strong free cash flow of $939M that provides stability but does not directly catalyze share price appreciation at current levels.
Risks & Conditions: The two biggest risks to the thesis are growth deceleration and multiple compression. This Hold rating would upgrade to a Buy if revenue growth re-accelerates sustainably above 10% YoY or if the forward P/E compresses below 20x without a deterioration in fundamentals. It would downgrade to a Sell if quarterly revenue growth turns negative or if operating margins contract significantly. Relative to its own recovery trajectory and sector peers, the stock is currently fairly valued to slightly overvalued.
Sign up to view all
ILMN 12-Month Price Forecast
The investment thesis for Illumina is in a transitional phase. The impressive profitability and cash flow recovery has been rewarded with a 76% stock surge, moving the narrative from 'turnaround' to 'steady execution.' The critical question is 'what's next?' At a 24x forward P/E, the market is pricing in a return to growth, but the current ~5% revenue run-rate does not yet confirm that. The neutral stance reflects this waiting period. The stance would turn bullish on confirmation of accelerating top-line growth (>10%) or bearish on signs of margin erosion or growth deceleration. Until then, it is a high-quality hold.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Illumina's 12-month outlook, with a consensus price target around $184.50 and implied upside of +30.0% versus the current price.
Average Target
$184.50
7 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
7
covering this stock
Price Range
$114 - $185
Analyst target range
Illumina is covered by 10 analysts, indicating solid institutional research interest. The consensus sentiment appears mixed, with recent actions showing a blend of Buy, Hold, and Underweight ratings, as evidenced by firm actions from Piper Sandler (Overweight), JP Morgan (Neutral), and Barclays (Underweight). The average target price is not explicitly provided in the data, so the implied upside or downside cannot be calculated; however, the distribution of ratings suggests a lack of strong, unified conviction on the near-term direction. The target range and specific price targets are not available in the provided dataset. The high target would likely assume successful execution on the core sequencing roadmap, sustained margin expansion, and no further strategic distractions. The low target would factor in risks of growth deceleration, competitive pressures, or integration challenges. The recent institutional ratings show no changes in stance (all actions maintained previous ratings), signaling analysts are in a 'wait-and-see' mode following the company's restructuring and refocus. The absence of a clear average target and wide rating dispersion points to higher uncertainty and a stock price that is likely to be more sensitive to quarterly execution and guidance.
Bulls vs Bears: ILMN Investment Factors
The bull case, centered on a remarkable profitability recovery and strong cash generation, currently holds stronger evidence, as reflected in the stock's powerful 76% annual rally. However, the bear case presents a formidable counter-argument centered on a premium valuation that demands accelerated growth which has yet to materialize. The single most important tension in the investment debate is whether Illumina's modest 5% YoY revenue growth can accelerate sufficiently to justify its elevated 24x forward P/E multiple, or if valuation compression will occur as the post-GRAIL recovery narrative matures.
Bullish
- Exceptional Profitability Recovery: Q4 2025 net income surged to $334 million, representing a robust net margin of 28.8%, a dramatic turnaround from the significant losses in 2024. This is supported by a high gross margin of 67.04% and a strong return on equity of 31.22%, indicating highly efficient capital use post-restructuring.
- Strong Free Cash Flow Generation: The company generated $939 million in trailing twelve-month free cash flow, providing ample internal funding for R&D and potential shareholder returns. This strong cash generation, coupled with a healthy current ratio of 2.08, underscores solid financial health and operational stability.
- Dominant Market Position & Technical Momentum: Illumina holds a dominant position as the platform standard in genomic sequencing. This strength is reflected in the stock's powerful 76.19% 1-year price change and its consistent outperformance of the S&P 500 by 13.61 percentage points over the last 3 months, signaling strong investor conviction in the recovery.
- Sequential Revenue Growth Trajectory: Revenue has grown sequentially from $1.041B in Q1 to $1.159B in Q4 of 2025, demonstrating a steady recovery path. The core Sequencing business, which drove $1.065B in Q4 revenue, is the primary engine for this top-line expansion.
Bearish
- Premium Valuation Demanding Flawless Execution: With a trailing PE of 24.52x, forward PE of 24.11x, and EV/EBITDA of 19.38x, Illumina trades at a significant premium to many sector peers. This rich valuation leaves little room for error and requires sustained high growth to justify current prices.
- Modest Underlying Revenue Growth: Despite the recovery, year-over-year revenue growth in Q4 2025 was only 4.98%. This modest pace may struggle to support the stock's premium valuation multiple if it does not accelerate meaningfully in coming quarters.
- High Volatility & Technical Overextension: The stock's beta of 1.424 indicates it is 42% more volatile than the market, amplifying downside risk. Furthermore, trading at 91.6% of its 52-week range suggests it is near-term overbought and vulnerable to a pullback, as seen in the -25.66% max drawdown earlier this year.
- Analyst Uncertainty & Lack of Conviction: Analyst coverage shows a mixed bag of Overweight, Neutral, and Underweight ratings with no recent changes, indicating a 'wait-and-see' mode and a lack of unified bullish conviction. This dispersion heightens uncertainty and price sensitivity to quarterly results.
ILMN Technical Analysis
The stock is in a strong, sustained uptrend over the past year, evidenced by a remarkable 76.19% 1-year price change. As of the latest close at $142.54, the price is trading near the upper end of its 52-week range, approximately 91.6% of the way from the low of $78.55 to the high of $155.53, indicating significant momentum but also potential overextension relative to its recent trading band. Recent momentum shows acceleration, with a 22.03% gain over 3 months and a 7.77% gain over 1 month, both substantially outperforming the broader market (SPY) by 13.61 and 2.17 percentage points, respectively, confirming the strength of the current trend. Short-term momentum remains robust and aligned with the longer-term uptrend, as the 1-month return of 7.77% builds upon the 3-month gain of 22.03%. This consistent upward pressure suggests strong buying interest, though the stock's high beta of 1.424 indicates it is approximately 42% more volatile than the market, which amplifies both gains and potential drawdowns. The price action shows a recovery from a sharp sell-off in early February 2026 (touching a low near $114), followed by a steady climb, indicating resilience and renewed investor confidence. Key technical levels are clearly defined, with immediate resistance at the 52-week high of $155.53 and major support at the 52-week low of $78.55. A decisive breakout above $155.53 would signal a continuation of the bull trend and potentially open the door to new highs, while a breakdown below the recent February low near $114 would challenge the uptrend's integrity. The stock's elevated beta of 1.424 underscores its high-risk, high-reward profile, necessitating careful position sizing given its propensity for larger swings than the overall market.
Beta
1.42
1.42x market volatility
Max Drawdown
-25.7%
Largest decline past year
52-Week Range
$79-$156
Price range past year
Annual Return
+68.5%
Cumulative gain past year
| Period | ILMN Return | S&P 500 |
|---|---|---|
| 1m | +6.8% | +4.6% |
| 3m | +18.3% | +8.3% |
| 6m | +14.6% | +12.5% |
| 1y | +68.5% | +25.0% |
| ytd | +5.6% | +8.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ILMN Fundamental Analysis
Revenue growth has returned but remains modest, with Q4 2025 revenue of $1.159 billion representing a 4.98% year-over-year increase. The multi-quarter trend shows sequential revenue growth from $1.041 billion in Q1 to $1.159 billion in Q4 of 2025, indicating a steady recovery trajectory. Segment data reveals the core Sequencing business, generating $1.065 billion, is the primary growth driver, while the legacy Microarray segment contributed a smaller $94 million, highlighting the company's dependence on its flagship technology for top-line expansion. Profitability has improved dramatically from the losses incurred in 2024, with Q4 2025 net income reaching $334 million, translating to a net margin of 28.8%. Gross margin remains robust at 67.04% for the quarter, consistent with the company's high-margin consumables business model. The operating margin for Q4 was 22.09%, demonstrating effective cost control and a significant turnaround from the operating losses posted in the first half of 2024, which were heavily impacted by large impairment charges related to GRAIL. The balance sheet shows solid financial health, with a current ratio of 2.08 indicating strong short-term liquidity. Debt levels are manageable, with a debt-to-equity ratio of 0.94. Most importantly, the company is generating substantial cash, with trailing twelve-month free cash flow of $939 million, providing ample internal funding for operations, R&D, and potential shareholder returns. The return on equity of 31.22% is exceptionally high, reflecting efficient use of shareholder capital post the restructuring and impairment charges.
Quarterly Revenue
$1.2B
2025-12
Revenue YoY Growth
+0.04%
YoY Comparison
Gross Margin
+0.67%
Latest Quarter
Free Cash Flow
$939000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ILMN Overvalued?
Given the company's positive net income of $334 million in the latest quarter, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE is 24.52x, while the forward PE is 24.11x, indicating the market expects earnings to remain relatively stable in the near term, with minimal growth priced in between the two metrics. Compared to sector averages, Illumina trades at a significant premium. For instance, its Price-to-Sales ratio of 4.81x is elevated for the Medical Diagnostics & Research industry, which often features lower multiples. The EV/EBITDA of 19.38x also suggests a rich valuation, likely justified by the company's market-leading position, high gross margins of ~67%, and its potential for normalized earnings growth as it moves past recent headwinds, though it demands flawless execution. Historically, the current trailing PE of 24.52x sits well below the extreme highs seen during the 2021-2022 period (e.g., over 90x) but is above the depressed levels seen during the 2024 loss-making phase. This positioning suggests the market has priced in a substantial recovery in profitability but remains cautious, not yet ascribing the hyper-growth multiples of the past. The stock is trading near the middle of its own historical valuation band, balancing recovery optimism with the memory of recent operational missteps.
PE
24.5x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -56x~2943x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
19.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is valuation compression, given the stock's premium multiples (24.11x forward P/E, 4.81x P/S) which are contingent on a reacceleration of growth beyond the current modest 5% YoY pace. While the balance sheet is healthy with a 0.94 debt-to-equity ratio, the company's revenue remains heavily concentrated in its Sequencing segment (>90% of sales), creating dependency on a single technology platform and exposing it to any slowdown in capital equipment spending or competitive disruption in that core market.
Market & Competitive Risks: As a high-beta (1.424) growth stock, Illumina is acutely sensitive to broader market rotations out of premium-valued healthcare technology names and increases in interest rates, which compress the present value of future earnings. The stock's 76% run-up over the past year has likely pulled forward much of the recovery optimism, increasing its vulnerability to profit-taking. While its market position is strong, the long-term risk of technological disruption from emerging sequencing methods or large tech companies entering the genomics space remains a persistent overhang.
Worst-Case Scenario: The worst-case scenario involves a combination of growth deceleration below 5%, a broader market sell-off that disproportionately hits high-beta stocks, and a loss of investor confidence in the management's refocused strategy, triggering multiple compression. This could realistically see the stock re-test its 52-week low of $78.55, representing a downside of approximately -45% from the current price of $142.54. The recent max drawdown of -25.66% in early 2026 provides a recent precedent for such volatility.
FAQ
The key risks are, in order of severity: 1) Valuation Compression: The rich 24x P/E is vulnerable if growth disappoints, potentially leading to a sharp decline. 2) Growth Stagnation: Revenue growth of ~5% may not be enough to drive the stock higher, risking a prolonged consolidation. 3) High Volatility: With a beta of 1.42, ILMN will fall more than the market in a downturn, as seen in its 25.66% max drawdown this year. 4) Competitive/Technological Disruption: While dominant, its >90% reliance on sequencing leaves it exposed to long-term shifts in the genomics landscape.
The 12-month forecast presents three scenarios. The Base Case (60% probability) sees the stock trading between $130 and $155, as steady execution but lack of growth acceleration leads to range-bound action. The Bull Case (25% probability) targets $155 to $175+ on accelerating revenue growth and multiple expansion. The Bear Case (15% probability) warns of a drop toward the $78-$110 range if growth stalls and multiples contract. The most likely outcome is the Base Case, where ILMN consolidates its massive gains while investors await clearer signs of its next growth phase.
ILMN is fairly valued to slightly overvalued based on near-term fundamentals. Its forward P/E of 24.11x and EV/EBITDA of 19.38x command a premium to many medical diagnostics peers, justified by its market dominance and high 67% gross margins. However, this premium is only sustainable if revenue growth accelerates from the current ~5% pace. Historically, its P/E is below the bubble highs of 2021 but above the depressed levels of 2024, placing it in a middle ground. The valuation implies the market expects a return to mid-to-high single-digit growth, not hyper-growth.
ILMN is a good stock for investors who already believe in the long-term genomics thesis and are willing to accept high volatility for a position in the market leader. However, for new money at current prices, the risk/reward is balanced. The stock has already rallied 76% in a year, pricing in much of the recovery, and its 24x forward P/E demands growth acceleration that has not yet materialized. It is a 'Hold' for most, and a 'Buy' only for those confident in imminent re-acceleration or those seeking a long-term core holding and willing to dollar-cost average.
ILMN is more suitable for a medium-to-long-term investment horizon of 2-3 years minimum. Its high beta of 1.424 makes it a poor candidate for short-term trading due to unpredictable volatility. As a non-dividend payer, the return thesis is entirely based on capital appreciation from business growth. The long-term story of genomic adoption remains intact, but the stock is in a transitional phase post-recovery. Investors need time for the company to either re-accelerate growth or for the valuation to become more compelling, making patience a key requirement.